Status:
RECRUITING
Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients
Lead Sponsor:
Leiden University Medical Center
Conditions:
Drug Monitoring
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The aim of the study is to perform a clinical validation of the analytical method for dried blood spot microsampling of cabozantinib, pazopanib, sunitinib, lenvatinib, imatinib, abiraterone, enzalutam...
Detailed Description
Rationale: Oral targeted anti-cancer drugs are a relatively novel group of drugs with a complex pharmacological profile. Due to the high pharmacokinetic interpatient variability and advised fixed dose...
Eligibility Criteria
Inclusion
- Willing and able to provide informed consent;
- 18 years of age or older;
- Using one or more of the following drugs: Cabozantinib, Pazopanib, Sunitinib, Lenvatinib, Imatinib, Abiraterone, Enzalutamide, Nivolumab, Ipilimumab, Pembrolizumab, Atezolizumab, Bevacizumab or Enfortumab vedotin
Exclusion
- Not able to sample themselves using a finger prick
Key Trial Info
Start Date :
October 6 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT06545292
Start Date
October 6 2025
End Date
July 1 2028
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leiden University Medical Center
Leiden, South Holland, Netherlands, 2333ZA